Loading
A phase 3 trial of Bevacizumab in ovarian cancer, run by AbbVie, active and no longer recruiting.
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer is a phase 3 interventional study registered as NCT05445778 by AbbVie, with 520 participants enrolled, started 2023-03-15 and due to reach its primary completion in 2027-04. Interventions recorded: Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab. Conditions listed: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer. No results are recorded here; the registry entry is the source.
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Ovarian cancer.
Shares AbbVie (incl. ImmunoGen, Capstan), Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Platinum-sensitive ovarian cancer, AbbVie (incl. ImmunoGen, Capstan), Ovarian cancer.
Shares Platinum-sensitive ovarian cancer, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.